Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.
Although treatment guidelines since 2016 recommend against further research into the use of dolutegravir monotherapy, it was disconcerting to have two oral presentations at AIDS 2018 reporting studies that still continued after the 2016 recommendatio...
24-week interim results from the INSPIRING study presented at CROI 2018 show that dolutegravir 50 mg twice daily is effective and well-tolerated in adults with HIV/TB receiving rifampicin-based TB treatment.
Two oral presentations and numerous posters at the 16th European AIDS Conference included new data on using dolutegravir-based dual ART (many with 3TC) as a switch option for people currently on stable three-drug ART.
Dolutegravir (DTG) was superior to lopinavir/ritonavir (LPV/r) in a comparison of DTG-based regimen versus the WHO-recommended second-line regimen.
Serious toxicities were seen in participants in a drug-drug interaction study of once-weekly isoniazid and rifapentine with once-daily dolutegravir, leading to its early termination.
"This is really the first step in demonstrating that two-drug regimens can be as effective as three-drug regimens," says Kimberly Smith, M.D., M.P.H.
Several studies at CROI 2017 reported a similar conclusion: reducing ART to dolutegravir monotherapy should be stopped.
Dolutegravir exposure was higher after crushing the originator fixed-dose combination tablet and after crushing was followed by enteral nutrition, compared to the whole tablet.